MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolb, N. S.
Right arrow Articles by Vander Jagt, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolb, N. S.
Right arrow Articles by Vander Jagt, D. L.

Aldose reductase-catalyzed reduction of acrolein: implications in cyclophosphamide toxicity

NS Kolb, LA Hunsaker and DL Vander Jagt

Department of Biochemistry, University of New Mexico School of Medicine, Albuquerque 87131.

Acrolein, a highly cytotoxic aldehyde, is a metabolic by-product of the antineoplastic agent cyclophosphamide and is responsible for the development of hemorrhagic cystitis, a serious side effect of cyclophosphamide therapy. Aldose reductase (EC 1.1.1.21), a member of the aldo-keto reductase superfamily, catalyzes the NADPH-dependent reduction of acrolein to allyl alcohol (Km = 80 microM, kcat = 87 min- 1). Aldose reductase is expressed at different levels in individuals. This suggests that individual differences in the reductive metabolism of acrolein may be a determinant of acrolein toxicity. In addition to being a substrate, acrolein also produces a time-dependent 7-20-fold increase in the activity of aldose reductase toward a variety of substrates. This involves initial binding of acrolein to a second site (Ks = 58 microM). Acrolein activation of aldose reductase results not only in higher kcat values for all substrates but also in higher Km values and decreased catalytic efficiencies. Acrolein activation of aldose reductase reduces its affinity for aldose reductase inhibitors.

Volume 45, Issue 4, pp. 797-801, 04/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Cancer Res.Home page
R. K. Thimmulappa, K. H. Mai, S. Srisuma, T. W. Kensler, M. Yamamoto, and S. Biswal
Identification of Nrf2-regulated Genes Induced by the Chemopreventive Agent Sulforaphane by Oligonucleotide Microarray
Cancer Res., September 15, 2002; 62(18): 5196 - 5203.
[Abstract] [Full Text] [PDF]


Home page
J AndrolHome page
T. Kobayashi, T. Kaneko, Y. Iuchi, S. Matsuki, M. Takahashi, I. Sasagawa, T. Nakada, and J. Fujii
Localization and Physiological Implication of Aldose Reductase and Sorbitol Dehydrogenase in Reproductive Tracts and Spermatozoa of Male Rats
J Androl, September 1, 2002; 23(5): 674 - 683.
[Abstract] [Full Text] [PDF]


Home page
Biol. Reprod.Home page
T. Kaneko, Y. Iuchi, S. Kawachiya, T. Fujii, H. Saito, H. Kurachi, and J. Fujii
Alteration of Glutathione Reductase Expression in the Female Reproductive Organs During the Estrous Cycle
Biol Reprod, November 1, 2001; 65(5): 1410 - 1416.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
H. G. Seo, T. Nishinaka, and C. Yabe-Nishimura
Nitric Oxide Up-Regulates Aldose Reductase Expression in Rat Vascular Smooth Muscle Cells: A Potential Role for Aldose Reductase in Vascular Remodeling
Mol. Pharmacol., April 1, 2000; 57(4): 709 - 717.
[Abstract] [Full Text]


Home page
Plant Physiol.Home page
S. Colrat, A. Latché, M. Guis, J.-C. Pech, M. Bouzayen, J. Fallot, and J.-P. Roustan
Purification and Characterization of a NADPH-Dependent Aldehyde Reductase from Mung Bean That Detoxifies Eutypine, a Toxin from Eutypa lata1
Plant Physiology, February 1, 1999; 119(2): 621 - 626.
[Abstract] [Full Text]


Home page
Pharmacol. Rev.Home page
C. Yabe-Nishimura
Aldose Reductase in Glucose Toxicity: A Potential Target for the Prevention of Diabetic Complications
Pharmacol. Rev., March 1, 1998; 50(1): 21 - 34.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1994 by the American Society for Pharmacology and Experimental Therapeutics